Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Lipocine Inc. entered into ATM Agreement with A.G.P./Alliance Global Partners valued at up to $10,616,169 of Shares; 3.0% of aggregate gross proceeds per sale (effective 2024-04-26).
- Action
- entry
- Agreement
- atm program
- Counterparty
- A.G.P./Alliance Global Partners
- Value
- up to $10,616,169 of Shares; 3.0% of aggregate gross proceeds per sale
- Effective
- 2024-04-26
Exact text from the filing
On April 26, 2024, Lipocine Inc. (the “Company”), entered into a sales agreement (the “ATM Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), as sales agent, pursuant to which the Company may offer and sell shares of common stock, par value $0.0001 per share (the “Shares”), from time to time, in an at-the-market public offering.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Lipocine Inc. terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. valued at terminated effective immediately upon notice; waiver of notice period (effective 2024-04-24).
- Action
- termination
- Agreement
- atm program
- Counterparty
- Cantor Fitzgerald & Co.
- Value
- terminated effective immediately upon notice; waiver of notice period
- Effective
- 2024-04-24
Exact text from the filing
On April 24, 2024, the Company provided notice to Cantor Fitzgerald & Co. (“Cantor”) of its election to terminate the Controlled Equity Offering SM Sales Agreement between them dated March 6, 2017 (the “Sales Agreement”).
View on SEC.gov